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Background: The cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) in an adjuvant
breast cancer treatment regimen is unknown.
Patients and methods: Women with resected node-positive or intermediate-risk node-negative HER2
overexpressing breast cancer and baseline left ventricular ejection fraction (LVEF) ≥55% were randomized (1 : 2) to
doxorubicin 60 mg/m2 (A) + cyclophosphamide 600 mg/m2 (C) every 21 days (q21d) for four cycles or PLD 35 mg/m2
+ C q21d + trastuzumab 2 mg/kg weekly (H) for 12 weeks. Both groups then received paclitaxel (Taxol, T) 80 mg/m2
with H for 12 weeks followed by H to complete 1 year. The primary end point was cardiac event rate or inability to
administer 1 year of trastuzumab.
Results: Of 181 randomized patients, 179 underwent cardiac analysis. The incidence of cardiac toxicity or inability to
administer trastuzumab due to cardiotoxicity was 18.6% [n = 11; 95% confidence interval (CI) 9.7% to 30.9%] with A +
C → T + H and 4.2% (n = 5; 95% CI 1.4% to 9.5%) with PLD +C +H → T + H (P = 0.0036). All events, except one,
were asymptomatic systolic dysfunction or mildly symptomatic heart failure. Mean absolute LVEF reduction at cycle 8
was greater with doxorubicin (5.6% versus 2.1%; P = 0.0014).
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Conclusion: PLD +C +H → T + H is feasible and results in lower early cardiotoxicity rates compared with A + C → T
+ H.
Key words: adjuvant therapy, anthracyclines, breast cancer, cardiotoxicity, pegylated liposomal doxorubicin,
trastuzumab
introduction
The concurrent or sequential administration of both
anthracyclines and taxanes is commonly recommended for
moderate- to high-risk breast cancer in the adjuvant setting.
The incorporation of trastuzumab for HER2-positive disease
improves disease-free and overall survival and has become a
standard of care [1–4]. Retrospective analyses of several studies
have observed that the benefit of adjuvant anthracycline-
containing regimens may be limited to patients with HER2
overexpressing disease [5–9], although the final results from
BCIRG 006, a large randomized phase III trial comparing
adjuvant anthracycline- and non-anthracycline-containing
trastuzumab-based regimens, is awaited [4].
Recent data suggest that the efficacy of adjuvant trastuzumab
may be greater when given concurrently with taxanes rather
than subsequent to anthracycline–taxane chemotherapy
regimens [10]. A small phase III trial has demonstrated that
concurrent administration of trastuzumab with neoadjuvant
chemotherapy including paclitaxel and fluorouracil, epirubicin,
and cyclophosphamide was associated with high pathological
complete response rates and low cardiac toxicity [11, 12].
Currently, however, this strategy is generally limited to non-
anthracycline regimens due to expectations of severe dose-
limiting cardiotoxicities with concurrent conventional
anthracyclines, especially doxorubicin, as observed in the
pivotal trial for metastatic HER2 overexpressing disease [13].
Compared with conventional anthracyclines, pegylated
liposomal doxorubicin (PLD) has been observed to be
significantly less cardiotoxic in the metastatic setting [14–16].
A Canadian multicenter single-arm phase II trial evaluated the
safety and efficacy of PLD 35 mg/m2 combined with
cyclophosphamide 600 mg/m2 every 3 weeks as first-line
treatment of metastatic breast cancer in 70 patients previously
exposed to adjuvant anthracyclines and observed an objective
response rate of 38%, median progression-free survival of 12.2
months, and a median survival time of 16.5 months [17]. The
most common grade 3 toxicity was palmar-plantar
erythrodysesthesia (PPE) occurring in seven patients (10%).
Asymptomatic, reversible cardiac dysfunction [left ventricular
ejection fraction (LVEF) drop of ≥10%] occurred in five
patients (7.1%).
Five phase II studies have examined concurrent
trastuzumab–PLD combinations for metastatic HER2
overexpressing breast cancer [18–22]. Among the total of 141
patients accrued, only 1 (0.7%) developed symptomatic
congestive heart failure (CHF). Milder cardiotoxicity,
consisting primarily of asymptomatic declines in LVEF,
occurred in 5%–25%. Across all studies, the most commonly
observed grade 3/4 toxic effects were PPE (13%–38%) and
neutropenia (17%–27%) with PLD plus trastuzumab.
Based on these findings, we hypothesized that substituting
PLD for doxorubicin may permit concurrent administration of
trastuzumab with anthracyclines in the adjuvant setting and
conducted this randomized phase II study evaluating the safety
of an adjuvant concurrent trastuzumab–anthracycline regimen.
patients and methods
This study was a multinational, parallel group, randomized open-label trial.
Subjects were randomized using a web-based randomization system in a 1 :
2 ratio (doxorubicin : PLD) and were stratified by age (<55 and ≥55 years).
patients
Eligible patients were women ≥18 years of age with operable node-positive
or intermediate-risk node-negative [23], HER2 overexpressing histologically
confirmed breast adenocarcinoma without evidence of metastatic disease.
Eligible node-positive patients had T1-3, N1-2 stage tumors. Eligible node-
negative patients had tumors >2 or >1 cm with at least one of the following
features: negative estrogen receptor/progesterone receptor status, grade 2–3
histology, peritumoral lymphovascular invasion, or age <35 years. HER2
overexpression was locally determined by FISH or immunohistochemistry
(3+). Patients had to have curative surgery including an axillary node
dissection or negative sentinel node biopsy before randomization. Baseline
LVEF ≥55% using multiple gated acquisition (MUGA) scan or
echocardiogram (ECHO) was required as was an Eastern Cooperative
Oncology Group performance status of zero to one and adequate bone
marrow, renal, and liver function.
Exclusion criteria included prior radiotherapy, chemotherapy, or
biotherapy for the currently diagnosed breast cancer; personal history of
breast cancer; history of non-breast malignancy within 5 years of study
entry except in situ carcinoma of the cervix or colon, melanoma in situ, or
basal or squamous cell carcinoma of the skin; serious cardiac illness
(including but not limited to history of, or active, CHF, history of or active
treatment of any form of cardiomyopathy, history of or medication-
requiring active angina pectoris, history of documented transmural
myocardial infarction, serious ventricular arrhythmias requiring medication
or implantable cardioverter–defibrillator therapy, uncontrolled
supraventricular arrhythmias, clinically significant valvular disease, or
poorly controlled hypertension [systolic blood pressure > 180 mmHg or
diastolic blood pressure > 100 mmHg]); grade >2 neuropathy; chronic
obstructive pulmonary disease requiring chronic treatment; clinically
significant active infection; and unstable diabetes mellitus.
end points
The primary end point of this study was to determine separately in each
arm the overall cardiac toxicity rate or the inability to administer
trastuzumab due to cardiotoxicity, for the planned treatment duration of 1
year, consistent with current standards of care. Events included cardiac
toxic effects, inability to administer trastuzumab during eight cycles of
chemotherapy, or inability to administer trastuzumab for a duration of 1
year. Each patient could contribute only one event to the primary end
point.
Cardiac toxic effects were categorized as level 1 (severe) or level 2 (mild).
Level 1 cardiac toxic effects were defined as cardiac death due to heart
failure, myocardial infarction or arrhythmia, or probable cardiac death
(defined as sudden unexpected death within 24 h of a definite or probable
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cardiac event) or severe symptomatic heart failure (New York Heart
Association [NYHA] class III or IV), concomitant with a drop in LVEF by
>10 percentage points from baseline and to <50% LVEF. Level 2 cardiac
toxic effects were defined as asymptomatic systolic dysfunction (NYHA
class I) or mildly symptomatic heart failure (NYHA class II) concomitant
with a drop in LVEF of >10 percentage points from baseline and to < 50%
LVEF.
Secondary end points included (i) incidence of overall, level 1 and 2
cardiac toxicity after four cycles of anthracycline-based chemotherapy, over
the eight total cycles of chemotherapy (only one event contributed per
patient), and during the 12 months following randomization, (ii) inability
to administer trastuzumab due to cardiotoxicity during the four cycles of
anthracycline-based chemotherapy, over the eight total cycles of
chemotherapy, and during planned trastuzumab monotherapy.
The protocol was initially designed to evaluate relapse-free survival in
the two treatment arms. Unfortunately, limitations in available resources
precluded this analysis.
treatment
Eligible subjects were randomized to receive doxorubicin 60 mg/m2 (A) i.v.
plus cyclophosphamide 600 mg/m2 (C) i.v. every 21 days for four cycles
(arm A; A + C) or PLD 35 mg/m2 i.v. plus cyclophosphamide 600 mg/m2 i.
v. given every 21 days plus trastuzumab (H) 2 mg/kg i.v. (first dose 4 mg/
kg i.v.) given weekly for 12 weeks (arm B; PLD + C +H). Both groups then
received paclitaxel 80 mg/m2 (T) i.v. with trastuzumab 2 mg/kg i.v. (4 mg/
kg i.v. for first dose if applicable) given weekly for 12 weeks (T +H),
followed by trastuzumab monotherapy to complete 1 year. Premedications
were used according to local institutional standards. Use of adjuvant
endocrine and radiation therapy was at the investigators’ discretion.
Primary prophylaxis with hematopoietic growth factors and antibiotics
was not permitted; secondary prophylaxis was allowed per institutional
standards. Dose reductions for grade 4 neutropenia lasting >7 days, febrile
neutropenia, or grade 4 thrombocytopenia were, for the first episode, 75%
reduction of doxorubicin and PLD and maintenance of paclitaxel and, for
the second episode, 50% reduction of doxorubicin and 75% reduction of
PLD and paclitaxel. Discontinuation of all three cytotoxic agents occurred
with a third episode.
For the first four cycles of chemotherapy, trastuzumab was discontinued
for level 1 or 2 cardiac toxicity or for LVEF <50%. For paclitaxel–
trastuzumab and single-agent trastuzumab, the protocol recommended that
trastuzumab be held for LVEF <50% concomitant with a drop of >10
points from baseline and resumed in 4 weeks if LVEF rose to ≥50% or
drop reduced to ≤10 perentage points from baseline.
Dose and schedule modifications of PLD for PPE varied according to
severity, duration, and occurrence of prior toxicity (see Table 1).
Symptomatic management of PPE was at investigator discretion and no
prophylactic therapies were permitted.
assessments
Cardiac assessments included a careful clinical evaluation for signs or
symptoms of CHF and LVEF measurement with either MUGA or ECHO.
The protocol recommended that one method be used consistently
throughout the study. A drop in LVEF was to be reconfirmed within 3–4
weeks of occurrence. Clinical cardiac assessment occurred at baseline,
before each cycle of therapy, post cycle 8, and at each follow-up visit. LVEF
assessment occurred at baseline, before cycle 5, post cycle 8, and then per
local institutional standards. After completion of chemotherapy, patients
were followed every 3 months for 1 year and every 6 months for an
additional year. For patients receiving post-study trastuzumab, the protocol
recommended LVEF assessment according to the trastuzumab package
insert, which includes repeat assessment every 3 months during treatment
and at 6 months, 12 months, and 24 months following cessation of
treatment [24]. Adverse events (AE) were graded according to the National
Cancer Institute—Common Toxicity Criteria for AE version 3.0.
statistics
Based on an assumed cardiac risk ratio of < 2, the required sample size for
80% power to detect this difference was 1050. Limitations in available
resources precluded accrual to this target; thus, no formal power
calculations were conducted and the statistical plan was modified to
determine event rates between the two treatment arms rather than allowing
for powered statistical comparisons. The planned sample size was 180
patients (60 patients in the A + C → T +H arm and 120 patients in the
PLD + C +H → T +H arm). Formal statistical sample size calculations
were not used to determine sample size; 95% confidence intervals were
calculated to provide the reference of estimation with 120 subjects for arm
B. Having ∼60 subjects in arm A provided at least 10% precision for
estimating the incidence of cardiac events in this arm. Demographic and
baseline characteristics were summarized with descriptive statistics.
Primary and secondary end points were analyzed on the intent-to-treat
(ITT) population (all randomized subjects who received at least one dose of
study treatment) and on the modified ITT population (the ITT population
with two patients excluded for baseline LVEF <55%). The pooled
incidences of level 1 and 2 cardiac events as well as the individual
incidences were calculated with 95% confidence. The frequency of patients
not being able to initiate or requiring hold or suspension of trastuzumab
was calculated. An interim analysis occurred when half of the subjects on
the PLD + C +H → T +H arm completed eight cycles and, at that time,
the independent data and safety management committee permitted the
trial to proceed to full accrual.
ethics
The study was conducted in accordance with ICH/GCP guidelines,
approved by local institutional review boards, and monitored by an
Table 1. Pegylated liposomal doxorubicin (PLD) dose and schedule modification for palmar-plantar erythrodysesthesia (PPE)
Toxicity grade Week after prior PLD dose
Week 3 Week 4 Week 5
1 without prior grade ≥3 PPE Redose without modification Redose without modification Decrease dose by 25%
1 with prior grade ≥3 PPE Hold 1 week Hold 1 week Decrease dose by 25%
2 Hold 1 week Hold 1 week Decrease dose by 25%
3 Hold 1 week Hold 1 week Study withdrawal
4 Hold 1 week Hold 1 week Study withdrawal
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independent data and safety management committee. All patients provided
written informed consent. The study is registered at ClinicalTrials.gov
(number NCT00550771).
role of the sponsor
Schering-Plough Corporation sponsored this study. The sponsor developed
the protocol in conjunction with a number of the investigators, provided
clinical study center oversight, supplied study drug, conducted statistical
analysis, and participated in manuscript review. Medical writing assistance
was provided by the sponsor. All authors reviewed, revised and approved
the content of the manuscript.
results
Between August 2007 and April 2009, 181 patients were
randomized from 38 centers in Europe, Australia, and Canada.
A total of 179 patients were analyzed for safety: 59 in arm A
(A + C → T +H) and 120 in arm B (PLD + C +H → T +H)
(Figure 1). Demographic and baseline characteristics were
balanced; although, there was a numerically higher proportion
of patients with >3 positive nodes and stage III disease in arm
A (Table 2).
treatment administered
In the ITT population, the mean cumulative anthracycline dose
administered was 233 mg/m2 of doxorubicin and 132 mg/m2
of PLD. Study treatment was received during cycles 5–8 by
91% of patients in each arm. The same proportion of patients
in each arm completed all eight cycles of chemotherapy (88%).
The proportion of anthracycline doses requiring modification
due to an AE was 6% in the A + C → T +H arm and 16% in
the PLD + C +H → T + H arm. Delivered dose intensity was
95% for doxorubicin and 83% for PLD.
Figure 1. CONSORT diagram. A + C → T +H, doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab; PLD + C +H → T +H,
pegylated liposomal doxorubicin plus cyclophosphamide plus trastuzumab followed by paclitaxel plus trastuzumab; LVEF, left ventricular ejection fraction.
Table 2. Baseline patient characteristics
Arm A
(A + C → T +H)
(N = 59)
Arm B (PLD +
C +H → T +H)
(N = 120)
No. (%) No. (%)
Mean age, years (range) 52.5 (30–71) 50.2 (20–83)
Mean BSA, m2 (range) 1.8 (1.39–2.38) 1.7 (1.42–2.39)
Race
White 55 (93.2) 116 (96.7)
Black 3 (5.1) 1 (0.8)
Other 1 (1.7) 3 (2.5)
ECOG performance status
0 52 (88.1) 115 (95.8)
1 6 (10.2) 5 (4.2)
Missing 1 (1.7) 0 (0)
ER status
ER+ 34 (57.6) 67 (55.8)
ER− 25 (42.4) 52 (43.3)
Unknown 0 (0) 1 (0.8)
PgR Status
PgR+ 25 (42.4) 54 (45.0)
PgR− 33 (55.9) 65 (54.2)
Unknown 1 (1.7) 1 (0.8)
Number of positive lymph nodes
0 25 (42.4) 47 (39.2)
1–3 18 (30.5) 47 (39.2)
4–9 11 (18.6) 19 (15.8)
≥10 5 (8.5) 7 (5.8)
TNM stage
I 10 (16.9) 24 (20.0)
II 27 (45.8) 65 (54.2)
III 22 (37.3) 31 (25.8)
A, doxorubucin; C, cyclophosphamide; ECOG, Eastern Cooperative
Oncology Group; ER, estrogen status; H, trastuzumab; PLD, pegylated
liposomal doxorubicin; PgR, progesterone receptor; T, paclitaxel; BSA,
body surface area.
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cardiac function and toxicity
Cardiac end points are summarized in Table 3. In the ITT
population, the overall incidence of cardiac toxicity or inability
to administer trastuzumab due to cardiotoxicity (the primary
end point) was 18.6% (n = 11; 95% CI, 9.7% to 30.9%) in the
doxorubicin arm and 4.2% (n = 5; 95% CI, 1.4% to 9.5%) in
the PLD arm (P = 0.0036). These percentages remained the
same in the modified ITT population (data not shown). The
risk ratio for doxorubicin relative to PLD was 4.4. Of the 16
patients who had an event (11 in the doxorubicin arm versus 5
in the PLD arm), 8 were aged ≥55 years. All of the events
occurred after cycle 4. One event met the criteria for level 1
cardiotoxicity, due to a myocardial infarction and subsequent
cardiac insufficiency (arm B). Of the remaining 15 events, 7
were due to protocol-defined LVEF criteria (an LVEF drop of
>10% to <50% and confirmed in 3–4 weeks), with 3 of the 7
events resulting in clinical symptoms and classified as NYHA
class II CHF. The remaining eight events were adjudicated by
the independent data and safety management committee, and
were all asymptomatic (NYHA class I). No cardiac deaths
occurred.
The mean LVEF was comparable between treatment groups
at baseline (64.0%, PLD + C +H → T +H and 64.4%, A + C →
T +H). The mean absolute reduction in LVEF from baseline to
cycle 8 was significantly greater in patients receiving
doxorubicin (5.6% versus 2.1%; P = 0.0014; Table 3, Figure 2).
In the modified ITT population, the mean absolute reduction
in the PLD arm was slightly greater at 2.2%.
noncardiac toxic effects
Grades 2–4 noncardiac toxic effects are summarized in Table 4.
The most common toxic effects of any grade were alopecia
(76.3%), fatigue (61.0%), and nausea (59.3%) in the
doxorubicin arm and PPE (66.7%), nausea (52.5%), and
alopecia (49.2%) in the PLD arm. Patients in the doxorubicin
arm experienced higher rates of alopecia (76.3% versus 49.2%),
fatigue (61.0% versus 40.8%), neutropenia (44.1% versus
22.5%), cough (27.1% versus 15.8%), and dizziness (18.6%
versus 9.2%). Patients in the PLD arm experienced higher rates
of PPE (66.7% versus 5.1%, all grades), rash (29.2% versus
10.2%), dyspepsia (20.0% versus 6.8%), and skin erythema
(15.0% versus 3.4%). Febrile neutropenia occurred more often
in the doxorubicin arm (8.5% versus 5.0%) with granulocyte
colony-stimulating factor as secondary prophylaxis
administered to 6 patients (10.2%) receiving doxorubicin and
10 patients (8.3%) receiving PLD.
discussion
The current study observed that trastuzumab given
concurrently with PLD plus cyclophosphamide followed by
paclitaxel plus trastuzumab appears to be safe from a cardiac
standpoint, with a protocol-defined early cardiotoxicity rate
that was lower than the comparator regimen of doxorubicin
plus cyclophosphamide followed by paclitaxel plus
trastuzumab. The overall incidence of cardiac toxicity or
inability to administer trastuzumab due to cardiotoxicity, the
primary end point, was 18.6% in the doxorubicin arm and
4.2% in the PLD arm despite the concurrent administration of
trastuzumab with PLD. Although, this difference was
statistically significant, with a P-value of 0.0036, it is important
to note that the study was not powered to detect significant
differences between the two treatment arms. No cardiac deaths
occurred on study.
Despite recent controversies surrounding the role of
anthracyclines in the adjuvant treatment of breast cancer, these
agents remain a cornerstone of therapy. Minimizing
anthracycline-associated cardiotoxicity is essential to maximize
safety, particularly when used in combination with
trastuzumab. Conventional anthracyclines are associated with
type I treatment-related cardiac dysfunction characterized by
cumulative, dose-dependent direct myocardial injury resulting
Table 3. Cardiac function and toxicity rates in the intent-to-treat
population
End point Arm A (A +
C → T +H)
(N = 59)
Arm B (PLD +
C +H → T +H)
(N = 120)
No. (%) No. (%)
Overall incidence of cardiac
toxicity (level 1 or 2) or inability
to administer trastuzumab
(primary end point)
11 (18.6) 5 (4.2)
95% CIa 9.7–30.9 1.4–9.5
P-valueb 0.0036
During cycles 1–8 of chemotherapy
Level 1 cardiac toxicityc 0 (0) 1 (0.8)
Cardiac deaths 0 (0) 0 (0)
Level 2 cardiac toxicityd 3 (5.1) 1 (0.8)
During 1 year of trastuzumab
Level 1 cardiac toxicityc 0 (0) 0 (0)
Level 2 cardiac toxicityd 10 (19.2) 4 (3.5)
Hold or suspend trastuzumab
due to cardiotoxicity
8 (15.4) 3 (2.6)
LVEF
Mean baseline LVEF, % (range) 64.4 (55–85) 64.0 (50–85)
Mean absolute LVEF change
from baseline to cycle 8, %
(range; SD)
−5.6 (−24.0 to
+6.0; 6.63)
−2.1 (−17.0 to
+15.0; 6.32)
P-valuee 0.0014
aComputed using the exact binomial method.
bTwo-tailed Fisher’s exact test; the study was not powered to detect
differences.
cCardiac death due to heart failure, myocardial infarction or arrhythmia, or
probable cardiac death defined as sudden, unexpected death within 24 h of
a definite or probable cardiac event, or severe symptomatic heart failure
concomitant with a drop in LVEF by >10 percentage points from baseline
and to <50% LVEF.
dAsymptomatic systolic dysfunction or mildly symptomatic heart failure
concomitant with a drop in LVEF by >10 percentage points from baseline
and to <50% LVEF.
eP-values based on an analysis of treatment differences in the change in
LVEF from baseline to week 25 adjusting for baseline differences.
A, doxorubicin; C, cyclophosphamide; CI, confidence interval; H,
trastuzumab; LVEF, left ventricular ejection fraction; PLD, pegylated
liposomal doxorubicin; SD, standard deviation; T, paclitaxel.
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in mostly irreversible myocardial injury, while trastuzumab is
associated with type II cardiac dysfunction that is dose-
independent, characterized by myocyte dysfunction rather than
injury, and is predominantly reversible [25]. Liposome
encapsulation and pegylation alter the cardiac safety profile of
anthracyclines by minimization of drug delivery to normal
tissues due to liposomal size, which limits passage through the
tight capillary junctions of nonmalignant tissue. This results in
the preferential targeting of the wide capillary junctions of
malignancy-related vasculature with lessened myocardial
Figure 2. Boxplots of left ventricular ejection fraction over time by treatment arm in the intent-to-treat population.
Table 4. Noncardiac toxic effects
Arm A (A + C → T +H) (N = 59) Arm B (PLD + C +H → T +H) (N = 120)
Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade 4
No. (%)
Any 27 (46) 21 (36) 7 (12) 46 (38) 56 (47) 5 (4)
Nausea 14 (24) 2 (3) 0 20 (17) 0 0
Alopecia
Grade 1 9 (15) — 30 (25) —
Grade 2 36 (61) — 29 (24) —
Diarrhea 7 (12) 2 (3) 0 9 (8) 0 0
Neutropenia 6 (10) 11 (19) 6 (10) 11 (9) 12 (10) 0
Neuropathy, peripheral 4 (7) 4 (7) 0 6 (5) 4 (3) 0
Mucositis 4 (7) 0 0 18 (15) 3 (2) 0
Asthenia 3 (5) 2 (3) 0 15 (12) 2 (2) 0
PPE 2 (3) 0 — 31 (26) 24 (20) —
Febrile neutropenia — 2 (3) 3 (5) — 5 (4) 1 (1)
Rash 0 0 0 11 (9) 5 (4) 0
A, doxorubicin; C, cyclophosphamide; H, trastuzumab; PLD, pegylated liposomal doxorubicin; PPE, palmar plantar erythrodysesthesia; T, paclitaxel.
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exposure to free doxorubicin resulting in a favorable cardiac
safety profile relative to conventional doxorubicin [14, 26].
PLD may therefore lessen anthracycline-induced oxidative
stress, as well as diminish the impact of the loss of neuregulin-
related cardioprotection induced by trastuzumab, thereby
maximizing the cardiac safety of a concurrent anthracycline–
trastuzumab regimen [27].
Rates of symptomatic cardiotoxicity are higher with
adjuvant trastuzumab compared with non-trastuzumab-
containing regimens, although event rates are low
(symptomatic/severe event rates for trastuzumab versus non-
trastuzumab regimens; 2% versus 0.45% in NSABP-B31/
NCCTG and 0.8% versus 0% in HERA) [28, 29]. Most
events are reversible with appropriate medical management,
although even with prolonged follow-up, recovery is <100%.
In the HERA trial, 5.1% of patients discontinued
trastuzumab due to cardiac toxicity and in the combined
NSABP B-31/NCCTG trials, 6.7% of patients did not begin
adjuvant trastuzumab due to an inadequate LVEF post AC
chemotherapy, with a further 18.9% discontinuing
trastuzumab due to cardiac toxic effects before the planned 1
year of therapy [3, 28]. In the combined analysis,
independent risk factors for cardiac toxicity included older
age and trastuzumab receipt but these variables did not allow
for the identification of a particular population or a baseline
LVEF value characterizing increased risk [29].
The current analysis is limited by the short duration of
follow-up, the absence of efficacy and quality of life data, and
the fact that the study was not powered to detect significant
differences between the two arms. As well, each patient could
contribute only one event to the primary end point and
therefore, the exact distribution of trastuzumab-withdrawal
events versus cardiac events could not be determined, although
significant overlap would be expected due to the
interrelationship between cardiac toxicity and incomplete
trastuzumab administration.
Efficacy data are not available from this trial and are needed
to fully evaluate the benefit of (i) replacing doxorubicin in the
A + C → T +H regimen with PLD and (ii) incorporating
trastuzumab concurrent with anthracycline-based
chemotherapy earlier in treatment. Non-inferiority of PLD
compared with doxorubicin has been established in the
metastatic setting, suggesting that replacing doxorubicin should
not compromise efficacy [14]. Quality of life data would be
important to assess the comparative impact and trade-off
between PPE and cardiotoxicity in the PLD versus doxorubicin
treatment arms, respectively.
The BACH trial is the first study to specifically examine the
safety of a concurrent anthracycline–trastuzumab regimen as
adjuvant therapy for HER2 overexpressing breast cancer.
Consistent with phase II trials in the metastatic setting
indicating that concurrent administration of PLD and
trastuzumab is feasible, results from the BACH trial suggest
that this strategy is safe, thereby potentially allowing for the
earlier incorporation of adjuvant trastuzumab in concurrent
treatment protocols [18–22]. The possible clinical benefit of
this strategy remains to be defined but would be most ideally
examined in a randomized phase III adjuvant trial comparing
the current strategy to an optimal non-anthracycline
trastuzumab-based regimen such as that under investigation in
BCIRG006 [docetaxel–carboplatin–trastuzumab (TCH)].
The cardiac safety analysis of this study suggests that
administering trastuzumab concurrent with PLD in the PLD +
C +H → T +H regimen is feasible and results in lower rates of
early cardiotoxicity and premature cessation of trastuzumab
due to cardiotoxicity, compared with A + C → T +H.
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Trastuzumab induces antibody-dependent cell-
mediated cytotoxicity (ADCC) in HER-2-non-amplified
breast cancer cell lines
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Background: Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by CD56 + natural killer (NK) cells
may contribute to the activity of trastuzumab in HER-2-amplified tumours. In this study, we investigated the possibility
that trastuzumab might induce ADCC against HER-2-non-amplified breast cancer cells.
Methods: Induction of NK cell-mediated ADCC was examined in trastuzumab-treated HER-2-non-amplified breast
cancer cell lines. HER-2 protein levels were also determined in tumour and autologous normal tissue samples from
patients with HER-2 negative breast cancer.
Results: Trastuzumab induced a significant ADCC response in the HER-2-amplified HCC1954 and SKBR3 cell lines,
and in all five of the non-amplified cell lines, which had low levels of detectable HER-2 by western blot (CAL-51, CAMA-
1, MCF-7, T47D, and EFM19). Trastuzumab did not induce ADCC in the K562 control cell line or MDA-MB-468, which
has very low levels of HER-2 detectable by enzyme-linked immunosorbent assay (ELISA) only. HER-2 protein was
detected by ELISA in 14/15 patient tumour samples classified as HER-2-non-amplified. Significantly lower levels of
HER-2 were detected in normal autologous tissue compared with tumour samples from the same patients.
Conclusion: Our results suggest that HER-2-non-amplified breast cancer cells, with low but detectable levels of HER-
2 protein, can bind trastuzumab and initiate ADCC.
Key words: ADCC, ERBB2, HER-2 low, HER-2-non-amplified breast cancer, trastuzumab
introduction
HER-2 protein overexpression (>30% of tumour cells, 3 + by
immunohistochemistry) or gene amplification (FISH HER-2/
CEP7 ratio >2.2), or both, occurs in 20%–25% of breast
cancers [1, 2], and is associated with a poorer prognosis [3, 4].
Treatment with trastuzumab, a humanised monoclonal
antibody directed against the extracellular domain of the HER-
2 protein, prolongs the survival of patients with early stage and
metastatic cancers whose tumours have HER-2 gene
amplification/protein overexpression [1, 5–8].
The major mechanisms of action of trastuzumab are
believed to be abrogation of intracellular HER-2 signalling
through pathways including PI3K/Akt and Ras/MAPK leading
to cell cycle arrest, reduction in angiogenesis, inhibition of
extracellular domain cleavage, and antibody-dependent cell-
mediated cytotoxicity (ADCC) [9–13].
Trastuzumab is active in combination with chemotherapy in
the HER-2-amplified metastatic disease setting [6, 14] but not
in HER-2-non-amplified, non-overexpressed metastatic breast
cancer [15]. The improvement in patient outcomes in the
metastatic setting led to four major studies in patients with
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